Galderma Enters Swiss Market Index, Forecasts Strong 2026 Sales
The dermatology group joined Switzerland's benchmark SMI less than three years after its March 2024 IPO, reporting US$5.21 billion in 2025 net sales.
Galderma Joins Benchmark Swiss Index
Galderma, the dermatology specialist, has been included in Switzerland’s Swiss Market Index (SMI), positioning it among the country’s 20 largest and most liquid publicly traded companies. This inclusion follows a period of robust growth since the company's initial public offering (IPO) on the SIX Swiss Exchange in March 2024.
The move places Galderma in a key benchmark index less than three years after its market debut, reflecting its expanding presence in the capital market. The SMI serves as a gauge for the performance of Switzerland's most significant listed entities.
Financial Performance and Growth Drivers
Galderma reported a significant increase in its net sales, climbing from US$4.41 billion in 2024 to US$5.21 billion in 2025. This growth was primarily fueled by strong performance across its Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology segments.
The company's momentum continued into the current year, with first-half 2026 sales rising by 24.6 percent year-on-year at constant currency rates. This positive financial trajectory led Galderma to revise its full-year sales growth guidance for 2026 to a range of 19–21 percent.
Ownership Structure and Market Position
The dermatology group's market position is further defined by its ownership structure, with L'Oréal holding a 20 percent stake in Galderma. The remaining 80 percent of the company's shares are in free float on the public market.
Inclusion in the SMI marks a significant milestone for Galderma as a publicly listed entity, showcasing the increasing scale of its specialized dermatology business. This development also underscores the company's growing significance within the broader Swiss capital market, attracting increased investor attention and liquidity.
Implications for Global Beauty Investment
Galderma's entry into the SMI enhances its visibility among international institutional investors, including those with mandates for global beauty and healthcare portfolios. This increased market profile could facilitate future capital raises or strategic partnerships for the company, potentially impacting its expansion strategies in high-growth beauty markets worldwide.
For Asian beauty investors and market observers, this development signals the continued financial strength of specialized dermatology companies. Companies seeking to track Galderma's regional market impact should look for specific geographic sales breakdowns in its upcoming 2026 full-year earnings reports.
Three newsletters, one newsroom.
The Beauty Brief delivers Asia's beauty week every Monday. Regulatory Radar tracks the rule changes that move markets. Trend Pulse decodes what consumers want next. All free to start.
